Last $13.75 USD
Change Today +0.03 / 0.22%
Volume 9.0M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 04/22/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$13.75
Previous Close
$13.72
Day High
$13.80
Day Low
$13.63
52 Week High
01/22/14 - $14.08
52 Week Low
04/23/13 - $7.28
Market Cap
18.2B
Average Volume 10 Days
12.9M
EPS TTM
$0.45
Shares Outstanding
1.3B
EX-Date
--
P/E TM
30.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Natick, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Senior Advisor
Total Annual Compensation: $607.6K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Announces FDA Approval of New Defibrillators and Heart Failure Devices

Boston Scientific Corporation has received FDA approval for its generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN(TM) MINI and INOGEN(TM) MINI ICDs, as well as the DYNAGEN(TM) X4 and INOGEN(TM) X4 CRT-Ds. The X4 line of quadripolar CRT-Ds offers 70% more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with the larger battery capacity in the industry. These newly approved devices continue the Boston Scientific history of projected longevity and a six-year CRT-D warranty. The small dimensions of the MINI ICD are up to 20% smaller by volume and up to 24% thinner than competitive devices from other manufacturers. ICDs and CRT-Ds are designed to treat patients suffering from heart failure and/or to provide protection to patients at risk of sudden cardiac death.

Vascular Solutions Announces Preliminary Injunction Against Boston Scientific's Guidezilla Catheter Vacated by Federal Circuit

Vascular Solutions Inc. announced that a three judge panel of the U.S. Court of Appeals for the Federal Circuit vacated the preliminary injunction that was previously issued by the District Court for the District of Minnesota effective January 13, 2014 against Boston Scientific's Guidezilla guide extension catheter. The Court's ruling on the preliminary injunction does not affect the underlying patent litigation, which is currently scheduled to be ready for trial on or after March 2015 in the District Court for the District of Minnesota.

Boston Scientific Signs Distribution Agreement with Amos Gazit

Boston Scientific BV has signed a distribution partnership agreement with Amos Gazit Ltd. in Israel. Under the new partnership, Amos Gazit Ltd. will market and distribute Boston Scientific's Interventional Cardiology - excluding the Watchman Left Atrial Appendage Occlusion device -, Peripheral Interventions, Endoscopy and Urology/Women's Health products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $13.75 USD +0.03

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $114.19 USD +0.06
Olympus Corp ¥3,115 JPY +65.00
Smith & Nephew PLC 874.50 GBp -1.00
St Jude Medical Inc $62.94 USD +0.32
Zimmer Holdings Inc $91.68 USD -0.23
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.8x
Price/Cash Flow 62.8x
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.